7月6日，Abivax S.A.盘前上涨6.46%，报152.5美元/股，成交额58.0万美元。消息面上，公司此前宣布承销商全额行使超额配售权，额外购入96万股ADS，总募资规模从8亿美元扩大至约9.2亿美元，净募集资金约8.74亿美元，该发行于本周一正式完成交割。
募集资金将用于核心药物obefazimod在美国的商业化推进及溃疡性结肠炎和克罗恩病的临床研发。此前公司公布ABTECT维持试验Part 2积极数据消除安全性争议，叠加发行规模由最初6亿美元两度上调并获超额配售全额认购，机构需求旺盛持续强化市场信心，股价维持在125美元发行价上方运行。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.